Australia
Austria
Belgium
China
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
India
Ireland
Italy
Japan
Kazakhstan
Latvia
Lithuania
Malaysia
Netherlands
Norway
Poland
Singapore
Slovenia
Spain
Sweden
Switzerland
Thailand
UK
Ukraine
Orion as an investment
Our strategy is focused on building well-being and growth driven by Innovative Medicines, while our diversified and profitable business portfolio provides stable cash flow.
Latest financial release
Stock exchange releases
- 9/11/2026 Orion Corporation: Acquisition of own shares during week 37, 2026
- 9/4/2026 Orion Corporation: Acquisition of own shares during week 36, 2026
- 9/4/2026 102,000 Orion Corporation A shares converted into B shares
- 8/27/2026 Orion Corporation to commence acquisition of own shares for its share-based incentive plans
Press releases
- 7/3/2026 Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026
- 6/30/2026 Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market
- 6/23/2026 Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission
- 5/30/2026 Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
Why Orion:
